Pneumococcal Vaccine Market Report 2026

Pneumococcal Vaccine Market Overview

• Pneumococcal Vaccine market size has reached to $9.4 billion in 2025 • Expected to grow to $12.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rising Prevalence Of Pneumococcal Contamination Drives Growth In Pneumococcal Vaccine Market • Market Trend: Breakthrough In Vaccine For Enhanced Adult Protection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the pneumococcal vaccine market include: • Pneumococcal conjugate vaccine (PCV) (Segmentation By Product Type) → Expected gain of $2250.71 Million • Intramuscular (Segmentation By Route of Administration) → Expected gain of $2207.43 Million • Public Health Agencies (Segmentation By Distribution Channel) → Expected gain of $1483.32 Million

What Is Covered Under Pneumococcal Vaccine Market?

The pneumococcal vaccine refers to a vaccination that offers defense against potentially fatal and severe pneumococcal infections caused by streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and sepsis. It is highly efficient in protecting infants from one of the most common causes of meningitis and other illnesses, such as acute ear infections. The main pneumococcal vaccines are Prevnar 13, synflorix, pneumovax23, and others. Prevnar 13 refers to a pneumococcal conjugate vaccine containing 13 distinct strains of Streptococcus pneumoniae and it is used in children and tested on immunocompromised patients to prevent pneumococcal disease. The various routes of administration include intravenous, intramuscular, and subcutaneous and are distributed via pharmacies, community clinics, public health agencies, and other distribution channels to end users such as pediatrics and adults.

What Is The Pneumococcal Vaccine Market Growth Forecast?

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $12.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to launch of next-generation pcv vaccines, expanding adult vaccination recommendations, growth in healthcare access in emerging economies, increasing antimicrobial resistance concerns, government funding for preventive immunization. Major trends in the forecast period include expansion of conjugate vaccines for broader serotype coverage, increased focus on pediatric and geriatric immunization programs, rising adoption of combination and booster vaccination strategies, strengthening public–private partnerships for immunization coverage, growth in preventive healthcare and national immunization schedules.

What Is The Driver Of The Pneumococcal Vaccine Market?

The increasing prevalence of pneumococcal contamination is expected to propel the growth of the pneumococcal vaccine market going forward. Pneumococcal contamination refers to any infection caused by bacteria called Streptococcus pneumoniae or pneumococcus, such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body to produce antibodies against pneumococcal bacteria to reduce or destroy disease-carrying bacteria and toxins to protect children, the elderly, and those with weakened immune systems from many types of pneumococcal infections. For instance, in July 2025, according to the Immunisation Coalition, a Australia-based, independent not-for-profit charity, cases of invasive pneumococcal disease (IPD) have steadily increased each year, growing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. Therefore, the increasing prevalence of pneumococcal contamination is driving the growth of the pneumococcal vaccine industry.

How Will The Drivers Impact Growth In The Global Pneumococcal Vaccine Market?

• Growing Aging Population (Medium) – The growing aging population will become a key driver of growth in the pneumococcal vaccine market by 2030. The aging global population is creating a larger at-risk group for pneumococcal infections such as pneumonia and meningitis, due to age-related immune decline, leading to a sustained rise in vaccine demand. In response, healthcare systems and governments are prioritizing preventive measures to lower elderly morbidity and long-term care costs. Pneumococcal vaccination is central to these strategies, strengthening both public immunization campaigns and private healthcare recommendations, thereby driving overall market growth. Additionally, many countries are expanding adult and senior immunization programs, particularly in regions such as North America, Europe and Asia. These programs increasingly incorporate pneumococcal vaccine as a routine preventive measure. This integrated approach is accelerating vaccine adoption across the aging population segment. As a result, the growing aging population is anticipated to contributing to a 1.5% annual growth in the market. • Rising Prevalence of Chronic Respiratory Diseases (Medium) – The rising prevalence of chronic respiratory diseases will emerge as a major factor driving the expansion of the pneumococcal vaccine market by 2030. Individuals with chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and bronchitis have impaired lung function, making them highly vulnerable to pneumococcal infections, which drives the need for preventive vaccination. Global and national medical guidelines increasingly recommend pneumococcal vaccine for these high-risk groups, encouraging routine immunization. The expanding elderly population, which is more prone to both chronic lung conditions and severe pneumococcal disease, further enlarges the target market. In parallel, rising healthcare spending on preventive care is prompting systems to prioritize vaccinations as a cost-effective strategy to reduce hospitalizations. Consequently, the accelerating rising prevalence of chronic respiratory diseases capabilities is projected to contributing to a 1.3% annual growth in the market. • Rising Need for Pediatric Vaccination (Low) – The rising need for paediatric vaccination processes will serve as a key growth catalyst for the pneumococcal vaccine market by 2030, Infants and young children are highly susceptible to pneumococcal diseases like pneumonia, meningitis and otitis media due to their immature immune systems, making early vaccination essential. This has led to the widespread inclusion of pneumococcal vaccine in national paediatric immunization schedules, often starting in infancy. Government initiatives to protect children, coupled with growing parental awareness and paediatrician endorsements, have significantly increased vaccine uptake. As a result, immunization coverage continues to rise, strengthening overall demand. Therefore, this rising need for paediatric vaccination operations is projected to supporting to a 0.8% annual growth in the market. • Growing Public Health Campaigns (Low) – The growing public health campaigns will become a significant driver contributing to the growth of the pneumococcal vaccine market by 2030. Public health campaigns play a crucial role in raising awareness about the dangers of pneumococcal infections such as pneumonia, meningitis and sepsis, encouraging preventive action through vaccination. By emphasizing the safety and effectiveness of pneumococcal vaccine particularly for vulnerable groups like infants, seniors and individuals with chronic conditions these initiatives drive higher acceptance and uptake. Campaigns also focus on reaching underserved populations in rural and low-income areas via mobile clinics, community health workers and targeted media. Consequently, the growing public health campaigns strategies is projected to contributing to a 0.5% annual growth in the market.

How Will The Restraints Impact Growth In The Global Pneumococcal Vaccine Market?

• Cold Chain and Storage Challenges (Medium) – Cold Chain and Storage Challenges will restrict the growth of the Pneumococcal Vaccine market during the forecast period. Pneumococcal vaccines require strict temperature-controlled storage and transportation to maintain efficacy. Cold chain requirements create logistical challenges and costs for vaccine distribution, particularly in developing regions. Cold chain failures can lead to vaccine waste and limited market reach, affecting growth. • High Cost of Vaccines (Low) – High Cost of Vaccines will restrict the growth of the Pneumococcal Vaccine market during the forecast period. Pneumococcal vaccines can be expensive, creating barriers for healthcare systems and individuals in developing regions. High vaccine costs affect government procurement decisions and vaccination program coverage. Cost constraints can limit vaccination rates and market growth, particularly in price-sensitive markets. • Impact of Trade War and Tariff (Low) – Impact of Trade War and Tariff will restrict the growth of the Pneumococcal Vaccine market during the forecast period. Vaccine production relies on imported ingredients, components, and equipment subject to trade tariffs. Trade barriers can increase production costs and affect vaccine availability. Trade tensions may also impact international vaccine distribution and public health programs.

Key Players In The Global Pneumococcal Vaccine Market

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Global Pneumococcal Vaccine Market Trends and Insights

Major companies operating in the pneumococcal vaccine market are innovating new products to increase their profitability in the market. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company launched the V116 vaccine. V116 is intended to target the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Compared to other pneumococcal vaccines, V116 has shown better immunogenicity for a variety of serotypes in adult populations, and it has also produced positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is currently in Phase 3 development.

What Are Latest Mergers And Acquisitions In The Pneumococcal Vaccine Market?

In December 2024, Sanofi SA, a France-based pharmaceutical company, expanded its collaboration with SK Bioscience Co. Ltd. to advance the development of its licensed pneumococcal conjugate vaccine. Through this collaboration expansion, Sanofi aims to accelerate late-stage development and strengthen its pneumococcal vaccine portfolio by leveraging SK Bioscience’s advanced vaccine manufacturing and development capabilities. SK Bioscience Co. Ltd. is a South Korea-based biotechnology company specializing in pneumococcal vaccine R&D and biomanufacturing.

What Defines the Pneumococcal Vaccine Market?

The pneumococcal vaccine market consists of sales of vaxneuvance, prevnar 20, pneumococcal conjugate vaccines (PCV)10, and pneumococcal conjugate vaccines (PCV)7. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pneumococcal Vaccine Market Report 2026?

The pneumococcal vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pneumococcal vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.